# Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

> **NCT02926638** · PHASE2,PHASE3 · TERMINATED · sponsor: **SWOG Cancer Research Network** · enrollment: 9 (actual)

## Conditions studied

- MET Positive
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7

## Interventions

- **DRUG:** Erlotinib Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Rilotumumab

## Key facts

- **NCT ID:** NCT02926638
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06-16
- **Primary completion:** 2015-01-12
- **Final completion:** 2016-10-12
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Drug company decided to terminate all sponsored clinical studies involving rilotumumab.
- **Last updated:** 2020-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02926638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02926638, "Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02926638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*